Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $459,396.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRYGet Free Report) insider Justin Chakma sold 32,814 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $14.00, for a total value of $459,396.00. Following the completion of the sale, the insider now directly owns 203,566 shares of the company’s stock, valued at $2,849,924. This represents a 13.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Justin Chakma also recently made the following trade(s):

  • On Wednesday, November 27th, Justin Chakma sold 25,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $14.39, for a total value of $359,750.00.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ SPRY opened at $14.51 on Friday. The stock has a market cap of $1.41 billion, a PE ratio of -28.45 and a beta of 0.90. The business has a fifty day moving average of $14.82 and a two-hundred day moving average of $12.01. ARS Pharmaceuticals, Inc. has a 52-week low of $4.76 and a 52-week high of $18.51.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in SPRY. nVerses Capital LLC bought a new position in shares of ARS Pharmaceuticals during the third quarter valued at $30,000. Russell Investments Group Ltd. acquired a new stake in shares of ARS Pharmaceuticals in the first quarter valued at $60,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of ARS Pharmaceuticals by 151.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after buying an additional 4,472 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in shares of ARS Pharmaceuticals in the second quarter valued at $87,000. Finally, J.W. Cole Advisors Inc. increased its stake in shares of ARS Pharmaceuticals by 10.8% in the second quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock valued at $131,000 after buying an additional 1,500 shares in the last quarter. 68.16% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

SPRY has been the subject of several research reports. Raymond James raised ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $18.00 to $22.00 in a research report on Tuesday, August 13th. William Blair raised ARS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Leerink Partners raised their target price on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research report on Friday, September 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, ARS Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $24.00.

Get Our Latest Research Report on SPRY

About ARS Pharmaceuticals

(Get Free Report)

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

See Also

Insider Buying and Selling by Quarter for ARS Pharmaceuticals (NASDAQ:SPRY)

Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.